Apollomics Inc. (NASDAQ:APLM) Short Interest Down 30.9% in March

Apollomics Inc. (NASDAQ:APLM) was the target of a significant decline in short interest in March. As of March 13th, there was short interest totaling 8,621 shares, a decline of 30.9% from the February 26th total of 12,471 shares. Based on an average daily volume of 7,156 shares, the short-interest ratio is currently 1.2 days. Approximately 0.8% of the shares of the stock are sold short.

Apollomics Stock Performance

Shares of Apollomics stock opened at $17.65 on Friday. The company’s 50 day moving average price is $19.51 and its two-hundred day moving average price is $18.52. Apollomics has a fifty-two week low of $3.66 and a fifty-two week high of $42.12.

Hedge Funds Weigh In On Apollomics

A hedge fund recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC bought a new position in Apollomics Inc. (NASDAQ:APLM) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned approximately 0.40% of Apollomics as of its most recent SEC filing. 19.13% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

APLM has been the subject of several recent analyst reports. Wall Street Zen upgraded Apollomics from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Apollomics in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.